SRC and breast carcinoma: In metastatic prostate cell line PC3, restoration of CD82 suppressed integrin-mediated activation of c-Met, leading to decreased activation of a protooncogene tyrosine kinase (Src) and subsequent deactivation of several Src substrates, including breast cancer anti-estrogen resistance 1 Cas family member (p130Cas), focal adhesion kinase (FAK) [30], and p130Cas-Crk (an adapter protein) coupling and deactivation of CUB domain containing protein 1 (CDCP1) [35].